Developed in collaboration with Impact Global Health (FKA Policy Cures Research) the 100 Days Mission Scorecard report gives a quantifiable state of preparedness for future pandemics. Currently countermeasures are unavailable for almost all R&D Blueprint Priority pathogens with the exception of COVID-19 and Zaire ebolavirus. Vaccines have been prioritised for R&D whilst therapeutics lag behind with fewer approved products and clinical candidates. On a positive note, the Scorecard shows that funding for “Disease X” (platform technologies) has been increasing however investment across diseases and countermeasures are required for effective pandemic preparedness.
High level findings:
- Vaccines R&D received the most funding compared to other product areas, totalling just under US$11.3bn between 2014 and 2022.
- In total, US$6.2bn was invested in therapeutics R&D from 2014 to 2022. This area has grown significantly since 2014, going from just $86m invested for Ebola therapeutics to a peak of US$2.0bn in 2021 at the height of the COVID-19 pandemic.
- Funding for diagnostics R&D, totalled US$1.3bn from 2014 to 2022.